The text starts here.

News Release

FOR IMMEDIATE RELEASE
January 30, 2004

Eisai Commences Another US Legal Action Over Aciphex(R) ANDA Filing

Eisai Co., Ltd.
Eisai Inc.
Eisai Commences Another US Legal Action Over Aciphex(R) ANDA Filing

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Soichi Matsuno) announce that they filed a lawsuit against Mylan* regarding its submission of an abbreviated new drug application (ANDA) to the FDA for Aciphex(R) (Active Ingredient Name: rabeprazole sodium, Product Name in Japan: Pariet(R)). The patent infringement action was filed by Eisai in the U.S. District Court for the Southern District of New York in New York City.


Eisai believes that its rabeprazole composition of matter patent is valid until its expiration date of May 8, 2013. Eisai intends to vigorously enforce and defend that patent.


Aciphex(R) is classified as a proton pump inhibitor that effectively suppresses gastric acid secretion while inhibiting enzyme activity during the last phase of stomach acid secretion. Aciphex(R) was launched in the U.S. in 1999 and is currently marketed in 70 countries worldwide, including Japan, the U.K. and Germany.


Eisai is a research-based pharmaceutical company that discovers, develops and markets new chemical compounds to satisfy global unmet medical needs.



* :
Mylan Pharmaceuticals, Inc. (Headquarters: West Virginia) and its parent company Mylan Laboratories, Inc. (Headquarters: Pennsylvania)

Contacts:
Public Relations Department
Eisai Co., Ltd.
81-3-3817-5120
Cathy Pollini
Corporate Public Relations
Eisai Inc.
1-201-287-2052